Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Milica Medved and Walter M. Stadler.

 
Connection Strength
 
 
 
0.867
 
  1. Medved M, Karczmar G, Yang C, Dignam J, Gajewski TF, Kindler H, Vokes E, MacEneany P, Mitchell MT, Stadler WM. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
    View in: PubMed
    Score: 0.299
  2. Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin P, Karrison T, Stadler WM. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.173
  3. Yang C, Karczmar GS, Medved M, Oto A, Zamora M, Stadler WM. Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med. 2009 Apr; 61(4):851-9.
    View in: PubMed
    Score: 0.104
  4. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.100
  5. Yang C, Karczmar GS, Medved M, Stadler WM. Multiple reference tissue method for contrast agent arterial input function estimation. Magn Reson Med. 2007 Dec; 58(6):1266-75.
    View in: PubMed
    Score: 0.095
  6. Yang C, Karczmar GS, Medved M, Stadler WM. Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations. Magn Reson Med. 2004 Nov; 52(5):1110-7.
    View in: PubMed
    Score: 0.077
  7. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4048-54.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.